ArticleFrontiers in endocrinology2025
Clinical pregnancy outcomes in young women with diminished ovarian reserve undergoing frozen embryo transfer: a comprehensive analysis with exploratory insights into endometrial aging.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of GnRH Agonist Pretreatment with Reproductive Outcomes in Women ≥35 years with Diminished Ovarian Reserve Undergoing Frozen Embryo Transfer: A Large Retrospective Cohort Study.International journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study compared pregnancy outcomes after frozen-thawed embryo transfer (FET) in infertile women aged <40 years with diminished ovarian reserve (DOR) versus normal ovarian reserve (NOR), incorporating exploratory analysis of potential endometrial aging factors. Methods: In this retrospective study, we analyzed the data of 1,362 patients aged <40 years who underwent FET between January and December 2024. Patients were categorized into two groups: the DOR (anti-Müllerian hormone [AMH] < 1.1 ng/mL, n = 136) and NOR (AMH ≥ 1.1 ng/mL, n = 1,226) groups. Pregnancy outcomes were compared after adjusting for confounding factors using inverse probability weighting. Additionally, exploratory immunohistochemical analysis of p16 expression was performed using endometrial samples from 16 patients (n = 8 per group). Results: After weighting, the clinical pregnancy rate was significantly lower in the DOR group than in the NOR group (47.0% vs. 58.3%, P = 0.040; odds ratio = 0.63, 95% confidence interval: 0.41-0.98). Exploratory analysis revealed that the expression of p16 was significantly higher in the endometrial cells of patients with DOR than in those of patients in the NOR group (P < 0.001). Furthermore, a trend toward lower clinical pregnancy rates was observed with higher p16 expression. Conclusion: These exploratory findings suggest that reduced pregnancy rates in young women with DOR may involve endometrial aging mechanisms; however, the preliminary nature and limited sample size for molecular analysis necessitate cautious interpretation and warrant validation in larger and well-controlled cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.